Anaheim Bio, a Leiden company spun out of Alesta Therapeutics before BioMarin acquired Alesta, has launched with an oversubscribed €40m Series A that gives it a runway into 2028.
Anaheim Bio announced the round on 5 November. The preclinical-stage biotech will use the money to move its lead candidate, ANA-1, towards the clinic, with first trials in people expected in 2027.
The company was formed in 2026 from programmes that Alesta Therapeutics spun out before its acquisition by BioMarin. Anaheim is based in Leiden.
The deal
The financing comes from Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital, all of them former Alesta investors. Anaheim describes the Series A as oversubscribed.
Chief executive Ilan Ganot said the money covers the next development stage. "This financing takes ANA-1 through IND-enabling studies and into Phase 1," he said. He added that the return of Alesta's legacy investors reflects their confidence in the programme and the team.
The investor bench is also represented on the board. Luc Dochez, managing partner at Droia Ventures, chairs it, and Droia's Janwillem Naesens sits alongside Dan Estes of Frazier Life Sciences and Laura Brass of Novartis Venture Fund. Ganot holds a seat, and John McHutchison, a former strategic adviser to Alesta, joins as an independent director.
The programme
ANA-1 is a small-molecule inhibitor designed to lower extracellular pyrophosphate (PPi) as a treatment for calcium pyrophosphate deposition disease (CPPD). CPPD is a form of inflammatory arthritis caused by calcium pyrophosphate crystals building up in and around the joints. It most often affects older adults and can bring sudden, recurring bouts of severe joint pain and swelling, as well as chronic arthritis.
The company puts the share of adults affected in Europe and the United States at about 4% to 7%. Current treatments focus on controlling inflammation and symptoms, and no approved therapy removes or dissolves the crystal deposits behind the disease, according to Anaheim.
The team and what comes next
Alongside Ganot, the management team includes chief scientific officer Matthias Van Woensel, chief financial officer Rick Dekker and interim chief medical officer Benit Maru.
Dochez said he looked forward to working with the former Alesta team again, and that ANA-1 gives it a shot at a large, underserved market in rheumatology. With the round closed, Anaheim's plan is to complete IND-enabling work, take ANA-1 into a Phase 1 study in 2027 and fund operations into 2028.





